This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
News|Webcasts|July 28, 2026
Expedited Regulatory Pathways for Biologics
Webinar Date/Time: Fri, Aug 21, 2026 11:00 AM EDT
Join the discussion on how expedited regulatory pathways are compressing review timelines and incentivizing domestic manufacturing, accelerating patient access to new biotherapies while maintaining rigorous safety standards.
Register Free:
Event Overview:
This episode of the BioPharm Drug Digest will examine strategic triggers that have thus far won expedited regulatory review for biologics in development. The episode will also address differences behind expedited regulatory pathways (e.g., RMAT, fast track, priority review, and breakthrough therapy) while exploring how these designations, alongside the new National Priority Voucher pilot program, aim to dramatically compress review timelines and incentivize domestic manufacturing for complex biologics and advanced therapies. We will also discuss whether these mechanisms are effectively keeping pace with the high volume of newer modalities, like cell and gene therapies, in the pipeline while maintaining safety standards.
Key Learning Objectives:
- Comparing expedited regulatory pathway designations
- Identifying strategic triggers for accelerated review
- Leveraging National Priority Vouchers for manufacturing
- Balancing pipeline speed and safety standards
Who Should Attend:
- Regulatory affairs and compliance professionals
- Biomanufacturing and operations leaders
- Clinical development and strategic planning officers
- Supply chain and global logistics managers
Speaker:
TBA
Register Free:
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Trending on BioPharm International
1
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
4
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
5